Kiniksa Pharmaceuticals International, plc
KNSA
Rank in Stocks
#2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Share Price
$79.61
Last synced: 2026-10-19
Market Cap
$6.21B
Change (1 day)
1.30%
Change (1 year)
104.18%
Country
GB
Trade Kiniksa Pharmaceuticals International, plc (KNSA)
Category
Healthcare
Number of shares outstanding for Kiniksa Pharmaceuticals International, plc (KNSA)
Number of shares outstanding as of June 2026: 77.58M
According to Kiniksa Pharmaceuticals International, plc latest financial reports and stock price the company's current number of shares outstanding is 77.58M. At the end of December 2023 the company had 70.06M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Kiniksa Pharmaceuticals International, plc (KNSA) from 2016 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 77.58M | 8.62% |
| 2024 | 71.42M | 1.95% |
| 2023 | 70.06M | 0.98% |
| 2022 | 69.38M | 1.17% |
| 2021 | 68.58M | 10.89% |
| 2020 | 61.84M | 14.42% |
| 2019 | 54.05M | 82.92% |
| 2018 | 29.55M | -8.99% |
| 2017 | 32.47M | 0.00% |
| 2016 | 32.47M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 445.06M | 473.70% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 18.05B | 23,165.10% |
HK
|
